Netflix, Comcast and Paramount Make Bids for Warner Bros.

Deon Nicholas, Co-founder and President of Forethought, announced that the company has achieved $1 billion in return on investment (ROI) for its clients by leveraging agentic AI to reduce costs, expedite resolutions, and enhance customer retention. This statement was made during an interview on Bloomberg's 'The Close' with Katie Greifeld and Scarlet Fu.

Jim Caron, CIO of Morgan Stanley Investment Management, predicts that inflation will not pose as significant a challenge in 2026, with 2025 expected to be a transitional year marked by a soft patch in the economy. He noted that while the labor market may experience initial weakening, it is anticipated to strengthen in the long run.

U.S. stocks experienced a notable increase as investors reacted positively to expectations of potential interest rate cuts, driven by comments from New York Fed President John Williams regarding a softening labor market. This optimism was reflected in the closing bell coverage by Bloomberg, featuring insights from hosts Scarlet Fu, Carol Massar, and Tim Stenovec.

HDGE ETF Co-Portfolio Manager Brad Lamensdorf discussed the launch of their new short stock fund, the AdvisorShares Ranger Equity Bear ETF, during an appearance on ‘ETF IQ’ with Katie Greifeld, Scarlet Fu, and Eric Balchunas. This fund aims to provide investors with a strategy to profit from declining stock prices.

Warner Bros. Discovery's flagship journalism brand CNN has removed its content from Apple News, marking a significant shift in the relationship between the two companies. This decision was reported on November 23, 2025, and reflects ongoing changes within both organizations.

Mohamed Mansour, co-owner of San Diego FC and co-founder of Man Capital, emphasized the potential growth of Major League Soccer (MLS) in the U.S. by aligning its schedule with FIFA's, during an interview on Bloomberg Markets with Scarlet Fu. He noted that the increasing interest in soccer among American fans presents a significant opportunity for the league.

Novo Nordisk's shares plummeted after the company announced that its Ozempic pill failed to slow the progression of Alzheimer's disease in two late-stage studies. This disappointing outcome has raised concerns about the drug's efficacy and the company's future in the Alzheimer's treatment market.